Value Proposition
- High cancer cell specificity by cell surface characteristics.
- High water solubility.
- Combination of oncolytic and anti-angiogenic properties.
Unmet Need
There currently are no peptides reported to have both oncolytic and anti-angiogenic activities. Additionally, drug development requires solubility in water; however, the reported oncolytic peptides, such as LTX-315, are not. Thus, there exists a need for peptides which exhibit both anti-cancer properties that are also favorable for drug development.
Technology Description
JHU researchers have developed peptides with anti-angiogenic and oncolytic properties while also being water soluble. They have developed 22 unique peptides with desirable solubility and anti-cancer properties. The researchers’ data shows that the peptides exhibit anti-angiogenic and oncolytic activity, capable of suppressing tumor growth.
Stage of Development
- In vitro studies have been conducted on the 22 peptide derivatives. Pre-clinical studies are planned.
- Looking for partners to identify a lead peptide derivative.
Data Availability: Data available upon request.
Publication:
Furukawa N, Yang W, Chao A, Patil A, Mirando A, Pandey N, Popel A. Chemokine-derived oncolytic peptide induces immunogenic cancer cell death and significantly suppresses tumor growth. Res Sq [Preprint]. 2023 Oct 3:rs.3.rs-3335225. doi: 10.21203/rs.3.rs-3335225/v1. PMID: 37886580; PMCID: PMC10602061.
